Class B drug legislation
Submission to Minister of Health, 12 December 2022
Resources /
Submissions /
-
Submissions
- Advanced Cardiac Life Support Requirements for PGY1 Interns
- Proposal to fund the contraceptive pill desogestrel
- Proposal to widen access to medicines for blood cancer, inflammatory bowel diseases, eczema and rheumatoid arthritis
- Proposal to change the regulatory and funding restrictions for stimulant treatments for ADHD
- Safety measures for the use of puberty blockers
- MedSafe Medical Classifications Committee (MCC) 73rd Meeting
- Treaty Principles Bill submission
- Unlocking the potential of active ageing
- Extension of the provisional vocational assessment period
- Proposal to increase the period of supply limit from 3 to 12 months
- Proposal to fund β-hCG low sensitivity urine test kits
- Hauora Māori Strategy
- Proposal to fund lung treatments, breast cancer, chronic obstructive pulmonary disease (COPD), prevention of RSV
- Agenda of Medicines Classification Committee meeting
- Strategy to Prevent and Minimise Gambling Harm
- Amendments to the Smokefree Environments and Regulated Products Act
- Proposal to remove the renewal criteria for stimulant treatments
- Proposal to fund lisdexamfetamine for ADHD
- Medical aspects of fitness to drive: a guide for health practitioners
- Land Transport (Drug Driving) Amendment Bill
- Proposal to allow pharmacists to provide paracetamol to children under 2 years of age receiving the Bexsero vaccine
- Proposal to enable many childhood vaccinations to be given in pharmacies
- Emergency Management Bill
- Inquiry into Climate Adaptation
- Ministry of Health Precision Health
- Cost of Treatment Regulations
- Women’s Health Strategy
- The Therapeutic Products Bill
- Class B drug legislation
- Smokefree Environments and Regulated Products
- PASE whitepaper: more than a disease-based model
- Diabetes Action Plan 2022-2027
- HDC Case 20HDC00866
- Proposal to fund Mirena and Jaydess IUDs on a Practitioner Supply Order
- Cremation regulations review
- Putting Patients First: Modernising health workforce regulation
- Proposal to fund Ryzodeg
- Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules
Also in this category
Submissions
Migrating potential patient safety risk: Omeprazole 40mg and Flecainide 100mg capsules
Submission to Pharmaceutical Society of New Zealand
View resource
Submissions
Putting Patients First: Modernising health workforce regulation
Submission to Ministry of Health
View resource